These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

446 related articles for article (PubMed ID: 12800187)

  • 41. Constitutive activation of c-kit by the juxtamembrane but not the catalytic domain mutations is inhibited selectively by tyrosine kinase inhibitors STI571 and AG1296.
    Ueda S; Ikeda H; Mizuki M; Ishiko J; Matsumura I; Tanaka H; Shibayama H; Sugahara H; Takai E; Zhang X; Machii T; Kanakura Y
    Int J Hematol; 2002 Dec; 76(5):427-35. PubMed ID: 12512837
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Maintenance of Clonogenic KIT(+) Human Colon Tumor Cells Requires Secretion of Stem Cell Factor by Differentiated Tumor Cells.
    Fatrai S; van Schelven SJ; Ubink I; Govaert KM; Raats D; Koster J; Verheem A; Borel Rinkes IH; Kranenburg O
    Gastroenterology; 2015 Sep; 149(3):692-704. PubMed ID: 25962936
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Targeting c-kit receptor in neuroblastomas and colorectal cancers using stem cell factor (SCF)-based recombinant bacterial toxins.
    Choudhary S; Pardo A; Rosinke R; Batra JK; Barth S; Verma RS
    Appl Microbiol Biotechnol; 2016 Jan; 100(1):263-77. PubMed ID: 26428235
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Expression of stem cell factor and c-kit in human malignant fibrous histiocytoma cell line (TNMY1).
    Nakatani T; Marui T; Yamamoto T; Hitora T; Akisue T; Kawamoto T; Nagira K; Fujita I; Matsumoto K; Yoshiya S; Kurosaka M
    Anticancer Res; 2003; 23(3B):2329-33. PubMed ID: 12894511
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Antiproliferative effects of imatinib mesylate on ZR‑75‑1 and MDA‑MB‑231 cell lines via PDGFR‑β, PDGF‑BB, c‑Kit and SCF expression.
    Kadivar A; Ibrahim Noordin M; Aditya A; Kamalidehghan B; Davoudi ET; Sedghi R; Akbari Javar H
    Int J Mol Med; 2018 Jul; 42(1):414-424. PubMed ID: 29620139
    [TBL] [Abstract][Full Text] [Related]  

  • 46. c-Kit mediates chemoresistance and tumor-initiating capacity of ovarian cancer cells through activation of Wnt/β-catenin-ATP-binding cassette G2 signaling.
    Chau WK; Ip CK; Mak AS; Lai HC; Wong AS
    Oncogene; 2013 May; 32(22):2767-81. PubMed ID: 22797058
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Imatinib mesylate (STI571; Glivec)--a new approach in the treatment of biliary tract cancer?
    Wiedmann M; Kreth F; Feisthammel J; Deininger M; Mössner J; Caca K
    Anticancer Drugs; 2003 Oct; 14(9):751-60. PubMed ID: 14551510
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Expression of SCF splice variants in human melanocytes and melanoma cell lines: potential prognostic implications.
    Welker P; Schadendorf D; Artuc M; Grabbe J; Henz BM
    Br J Cancer; 2000 Apr; 82(8):1453-8. PubMed ID: 10780526
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Aberrant autophosphorylation of c-Kit receptor in canine mast cell tumor cell lines.
    Takeuchi Y; Fujino Y; Watanabe M; Nakagawa T; Ohno K; Sasaki N; Sugano S; Tsujimoto H
    Vet Immunol Immunopathol; 2010 Oct; 137(3-4):208-16. PubMed ID: 20591500
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Elimination of human lung cancer stem cells through targeting of the stem cell factor-c-kit autocrine signaling loop.
    Levina V; Marrangoni A; Wang T; Parikh S; Su Y; Herberman R; Lokshin A; Gorelik E
    Cancer Res; 2010 Jan; 70(1):338-46. PubMed ID: 20028869
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Expression of imatinib mesylate-targeted kinases in endometrial carcinoma.
    Slomovitz BM; Broaddus RR; Schmandt R; Wu W; Oh JC; Ramondetta LM; Burke TW; Gershenson DM; Lu KH
    Gynecol Oncol; 2004 Oct; 95(1):32-6. PubMed ID: 15385107
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Antiproliferation effect of imatinib mesylate on MCF7, T-47D tumorigenic and MCF 10A nontumorigenic breast cell lines via PDGFR-β, PDGF-BB, c-Kit and SCF genes.
    Kadivar A; Kamalidehghan B; Akbari Javar H; Karimi B; Sedghi R; Noordin MI
    Drug Des Devel Ther; 2017; 11():469-481. PubMed ID: 28260860
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The G-quadruplex ligand, SYUIQ-FM05, targets proto-oncogene c-kit transcription and induces apoptosis in K562 cells.
    Shen FH; Jin J; Li J; Wang Y; Zhu SH; Lu YJ; Ou TM; Huang ZS; Huang M; Huang ZY
    Pharm Biol; 2013 Apr; 51(4):447-54. PubMed ID: 23363047
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Imatinib inhibits various types of activating mutant kit found in gastrointestinal stromal tumors.
    Chen H; Isozaki K; Kinoshita K; Ohashi A; Shinomura Y; Matsuzawa Y; Kitamura Y; Hirota S
    Int J Cancer; 2003 May; 105(1):130-5. PubMed ID: 12672043
    [TBL] [Abstract][Full Text] [Related]  

  • 55. TrkA expression in peripheral neuroblastic tumors: prognostic significance and biological relevance.
    Shimada H; Nakagawa A; Peters J; Wang H; Wakamatsu PK; Lukens JN; Matthay KK; Siegel SE; Seeger RC
    Cancer; 2004 Oct; 101(8):1873-81. PubMed ID: 15386308
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Autocrine growth of small cell lung cancer mediated by coexpression of c-kit and stem cell factor.
    Krystal GW; Hines SJ; Organ CP
    Cancer Res; 1996 Jan; 56(2):370-6. PubMed ID: 8542594
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Kit and PDGFR-alpha activities are necessary for Notch4/Int3-induced tumorigenesis.
    Raafat A; Zoltan-Jones A; Strizzi L; Bargo S; Kimura K; Salomon D; Callahan R
    Oncogene; 2007 Feb; 26(5):662-72. PubMed ID: 16878155
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The c-kit tyrosine kinase inhibitor STI571 for colorectal cancer therapy.
    Attoub S; Rivat C; Rodrigues S; Van Bocxlaer S; Bedin M; Bruyneel E; Louvet C; Kornprobst M; André T; Mareel M; Mester J; Gespach C
    Cancer Res; 2002 Sep; 62(17):4879-83. PubMed ID: 12208734
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Paradoxical and contradictory effects of imatinib in two cell line models of hormone-refractory prostate cancer.
    Cardoso HJ; Vaz CV; Correia S; Figueira MI; Marques R; Maia CJ; Socorro S
    Prostate; 2015 Jun; 75(9):923-35. PubMed ID: 25786656
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Expression of KIT and PDGFR is associated with a good prognosis in neuroblastoma.
    Shimada A; Hirato J; Kuroiwa M; Kikuchi A; Hanada R; Wakai K; Hayashi Y
    Pediatr Blood Cancer; 2008 Feb; 50(2):213-7. PubMed ID: 17941064
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.